166 related articles for article (PubMed ID: 37914764)
1. Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging.
Maurer A; Gstrein NA; Dimitriou F; Sartoretti T; Schaab JA; Looman EL; Balermpas P; Rupp NJ; Freiberger SN; Soyka MB; Holzmann D; Mauthe T; Mueller SA; Beintner-Skawran S; Messerli M; Kenkel D; Huellner MW; Meerwein CM
Sci Rep; 2023 Nov; 13(1):18847. PubMed ID: 37914764
[TBL] [Abstract][Full Text] [Related]
2.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
3. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
4. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.
Samstein RM; Carvajal RD; Postow MA; Callahan MK; Shoushtari AN; Patel SG; Lee NY; Barker CA
Head Neck; 2016 Sep; 38(9):1310-7. PubMed ID: 27043023
[TBL] [Abstract][Full Text] [Related]
5. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
6. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
7. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
[TBL] [Abstract][Full Text] [Related]
9. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
11. The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.
Haerle SK; Soyka MB; Fischer DR; Murer K; Strobel K; Huber GF; Holzmann D
Eur Arch Otorhinolaryngol; 2012 Jan; 269(1):127-33. PubMed ID: 21713453
[TBL] [Abstract][Full Text] [Related]
12. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
[TBL] [Abstract][Full Text] [Related]
13. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
15. The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography.
Berberich C; Mustafa M; Zhuwu Y; Gaa J; Krackhardt A; Nekolla SG
Melanoma Res; 2023 Jun; 33(3):199-207. PubMed ID: 36866631
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
[TBL] [Abstract][Full Text] [Related]
17. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
18. Is there a link between very early changes of primary and secondary lymphoid organs in
Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
[TBL] [Abstract][Full Text] [Related]
19. Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.
Scherzad A; Stöth M; Meyer TJ; Haug L; Gehrke T; Schilling B; Meierjohann S; Scheich M; Hagen R; Gesierich A; Hackenberg S
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4215-4223. PubMed ID: 37272953
[TBL] [Abstract][Full Text] [Related]
20. Whole-body hybrid positron emission tomography imaging yields clinically relevant information in the staging and restaging of sinonasal tumors.
Maurer A; Meerwein CM; Soyka MB; Grünig H; Skawran S; Mühlematter UJ; Messerli M; Mader CE; Husmann L; Rupp NJ; Holzmann D; Huellner MW
Head Neck; 2021 Nov; 43(11):3572-3585. PubMed ID: 34515399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
